ESR1 PvuII (rs2234693 T>C) polymorphism and cancer susceptibility: Evidence from 80 studies

	ESR1 PvuII (rs2234693 T>C) polymorphism and cancer susceptibility: Evidence from 80 studies
	Ma, Yunzi; Liu, Xiaoqi; Huang, Jiawen; Lin, Huiran; Xiong, Lingjuan; Lao, Haiyan
刊名	JOURNAL OF CANCER
	2018
文献子类	期刊论文
英文摘要	Emerging epidemiological researches have been performed to assess the association of ESR1 PvuII (rs2234693 T> C) polymorphism with the risk of cancer, yet with conflicting conclusions. Therefore, this updated meta-analysis was performed to make a more accurate evaluation of such relationship. We adopted EMBASE, PubMed, CNKI, and WANFANG database to search relevant literature before January 2018. Odds ratios (ORs) and 95% confidence intervals (CIs) were employed to estimate the relationship strengths. In final, 80 studies (69 publications) involving 26428 cases and 43381 controls were enrolled. Our results failed to provide significant association between overall cancer risk and PvuII polymorphism under homozygous (TT vs. CC) and heterozygous (TT vs. CT) models. Statistically significant relationship was only observed for PvuII polymorphism in allele model T vs. C (OR= 0.95, 95% CI= 0.91-0.99). Stratification analysis by cancer type suggested that T genotype significantly decreased prostate cancer risk (TT vs. CC: OR= 0.79, 95% CI= 0.66-0.94; T vs. C: OR= 0.89, 95% CI= 0.82-0.98), Leiomyoma risk (T vs. C: OR= 0.82, 95% CI= 0.68-0.98), and HCC risk (TT vs. CC: OR= 0.45, 95% CI= 0.28-0.71; T vs. C: OR= 0.67, 95% CI= 0.47-0.95). Furthermore, significantly decreased risk was also found for Africans, population-based and hospital-based studies in the stratified analyses. These results suggest that ESR1 PvuII (rs2234693 T> C) polymorphism may only have little impact on cancer susceptibility. In the future, large-scale epidemical studies are warranted to verify these results.
URL标识	查看原文
语种	英语
内容类型	期刊论文
源URL	[http://ir.siat.ac.cn:8080/handle/172644/14866]
专题	深圳先进技术研究院_其他
推荐引用方式 GB/T 7714	Ma, Yunzi,Liu, Xiaoqi,Huang, Jiawen,et al. ESR1 PvuII (rs2234693 T>C) polymorphism and cancer susceptibility: Evidence from 80 studies[J]. JOURNAL OF CANCER,2018.
APA	Ma, Yunzi,Liu, Xiaoqi,Huang, Jiawen,Lin, Huiran,Xiong, Lingjuan,&Lao, Haiyan.(2018).ESR1 PvuII (rs2234693 T>C) polymorphism and cancer susceptibility: Evidence from 80 studies.JOURNAL OF CANCER.
MLA	Ma, Yunzi,et al."ESR1 PvuII (rs2234693 T>C) polymorphism and cancer susceptibility: Evidence from 80 studies".JOURNAL OF CANCER (2018).